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A patient required mitral valve replacement following ineffective antibiotic treatment of
enterococcal endocarditis caused by Streptococcusfaecium. Endocarditis had relapsed despite
therapy with ampicillin and tobramycin for six weeks. A second relapse had occurred following
treatment with penicillin and gentamicin. Initial failure of antibiotic therapy may be related to
the known lack of in vitro and in vivo synergy between penicillin and tobramycin against S.
faecium. Effective therapy of enterococcal endocarditis requires considerations of bacterial
speciation, determination ofhigh-level aminoglycoside resistance, and preferably adequate an-
tibiotic synergy studies to assure effective therapy.
INTRODUCTION
Enterococcal endocarditis requires special therapeutic considerations because the
responsible organisms are relatively penicillin-resistant streptococci which require
synergistic combinations of antibiotics to achieve acceptable cure rates [1,2]. The
group D enterococci include three main species S. faecalis, S. faecium, and S.
durans. S. faecium cause a minority of all cases of enterococcal endocarditis, in
those instances in which enterococci have been speciated [3], but they have been
more resistant both to penicillin and penicillin-aminoglycoside combinations than S.
faecalis [4,5,6].
We describe a 64-year-old man with S. faecium endocarditis in whom a six-week
course of ampicillin and tobramycin, followed by additional courses of penicillin
and other aminoglycosides, failed to eradicate theorganism from thepatient's mitral
valve. This case is of interest because therapeutic failure of ampicillin and
tobramycin in S. faecium endocarditis has not been reported previously, but might
have been predicted on the basis of previous in vitro and in vivo studies [6].
Although the need for both a penicillin derivative and an aminoglycoside in the
therapy of enterococcal endocarditis is widely known, it is important to distinguish
between the differing efficacies of penicillin-aminoglycoside combinations for
treating various species of enterococci such as S. faecium.
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CASE REPORT
A 64-year-old male was in good health until December 1980, when he noted inter-
mittent night sweats, malaise, fever, and fatigue. He received oral erythromycin for
14 days with transient improvement of symptoms. However, after completing
therapy, symptoms reappeared and he noted a 15-pound weight loss with low-grade
fever (99-100.5°F) during the two months preceding admission. There was no
previous history of rheumatic or congenital heart disease.
In March 1981, the patient was admitted to his community hospital where evalua-
tion revealed a new apical systolic murmur radiating to the axilla. There were no
petechiae, Janeway lesions, Osler's nodes, Roth spots, or splenomegaly. The
hematocrit was 34.8 percent, WBC count 9,300 cells per cu mm with a differential
count of 67 segmented forms, 9 bands, 15 lymphocytes, 7 monocytes, 1 eosinophil,
and 1 basophil. The erythrocyte sedimentation rate (ESR) was 62 mm per hour
(nl < 10 mm per hour) and the serum rheumatoid factor titer was 1:320. Chest films
and electrocardiogram werereportedly normal. Group D streptococcigrew from three
sets of blood cultures. Enterococcal endocarditis was diagnosed and he was treated
with six weeks ofparenteral ampicillin (12 grams per day) and tobramycin (3 mg per
kg per day). Resolution of symptoms occurred within several days after antibiotics
were begun. Serum bactericidal titers against the organism, obtained during peak
antibiotic levels, were 1:8 or greater on several occasions, and blood cultures were
negative while the patient was receiving antibiotics. M-mode echocardiography
demonstrated left atrial enlargement but no definable abnormalities of the mitral or
aortic valves. Intravenous pyelogram, oral cholecystogram, cystoscopy, liver-spleen
scan, and upper and lower gastrointestinal series were normal except for a few
sigmoid diverticuli. Flexible signoidoscopy demonstrated both a small perianal
fissure and hemorrhoids. Blood cultures two weeks after therapy were negative.
SecondAdmission (June 19-August 4, 1981)
In June 1981, he again noted intermittent fever, night sweats, and fatigue. Group
D streptococci grew from three sets of blood cultures and he was admitted to the
West Haven VA Medical Center for recurrent endocarditis. On examination a
somewhat louder apical systolic murmur was noted. The ESR was 50 mm/hour and
rheumatoid factor titer was 1:320. Serum complement levels were normal and
cryoglobulins were not detectable. Chest films, EKG, and urinalysis were normal.
Cardiac M-mode echocardiogram revealed a globular mass attached to the posterior
mitral valve leaflet with prolapse into a slightly enlarged left atrium. A two-
dimensional echocardiogram confirmed mitral valve prolapse and suggested a
posterior leaflet vegetation. Gallium citrate scan was negative.
Three separate morphologic colony variants were isolated from blood, each iden-
tified as S. faecium by Dr. R.R. Facklam (Center for Disease Control, Atlanta,
Georgia). The patient received intravenous penicillin (20 million units per day) and
gentamicin (3 mg per kg per day) for six weeks with improvement. Peak serum
bactericidal titers of 1:8 or greater were achieved against two ofthe colony variants;
however, against the large colony morphotype, a titer of only 1:2 was obtained. An
enlarged left atrium with intermittent fluttering and prolapse ofthe mitral valve was
noted on echocardiography three weeks into therapy. Multiple blood cultures taken
while the patient was receiving antibiotics were negative, as were those obtained 48
and 72 hours after discontinuation of antibiotics.
244S. FAECIUM ENDOCARDITIS
Third Admission (August 12-October 4, 1981)
Withing a week following discharge, the patient again developed fever, nocturnal
sweats, and malaise. S. faecium (large colony morphotype, and poorly growing
small colony morphotype) grew from six sets of blood cultures obtained on admis-
sion. Penicillin (30 million units/day) and gentamicin (3 mg/kg/day) were again ad-
ministered, initially achieving peak serum inhibitory and bactericidal dilutions of
1:16 and 1:8 against the organism, respectively. However, the organism had a low-
level resistance to streptomycin (MIC < 125 /Ag/ml), and streptomycin (2 grams per
day) was substituted for gentamicin two weeks into antibiotic therapy. Repeat
echocardiograms showed irregular and shaggy densities of both mitral valve leaflets
with partial prolapse. Cardiac catheterization demonstrated marked mitral valve
prolapse with mitral regurgitation. A radiolucent filling defect was noted, suggesting
a coronary artery embolus at the origin ofthe left anterior descending (LAD) artery,
causing 75 percent occlusion of the lumen. The patient underwent mitral valve
replacement, receiving a number 31 porcine Hancock bioprosthesis and bypass graft
to the midportion of the LAD. The mitral valve was thickened with several ruptured
chordae of the posterior leaflet noted, but no vegetations. The aortic valve appeared
normal, with no visible septal or ring abscesses. The occlusion in the LAD was not
approached to avoid embolizing distal fragments.
Histopathologically the mitral valve showed mild fibrosis and myxoid degenera-
tion without inflammatory changes. Bacterial and fungal stains were negative but S.
faecium grew from fragments of the resected valve. Following surgery the patient
received six additional weeks parenteral penicillin and streptomycin. Repeat blood
cultures on this regimen and following therapy were negative. Evaluation six months
following discontinuation of antibiotics showed no evidence of recurrent endocar-
ditis.
LABORATORY EVALUATION
The minimum inhibitory and bactericidal concentrations of penicillin, ampicillin,
and tobramycin against the S. faecium isolated from the patient's blood cultures
TABLE 1
Minimum Inhibitory and Bactericidal Concentrations of Antibiotics,
Against Streptococcusfaecium Isolates from Blood Cultures
Date Penicillin Ampicillin Tobramycin
Organism Isolated MIC MIC MBC MIC MBC
S. faecium, prior
to ampicillin/
tobramycin therapy 3/17/81 2 1 2 >32 >32
S. faecium, after
ampicillin/
tobramycin therapy
a. Large colony
variant 6/16/81 2 1 1 >32 >32
b. Medium colony
variant 6/16/81 2 1 2 32 32
c. Small colony
variant 6/16/81 4 2 4 >32 >32
aMIC and MBC are minimum inhibitory and bactericidal concentrations of antibiotics, respectively,
in tig/ml.
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FIG. 1. Time-kill curve demonstrat-
3- \ "'' ing the effects of various penicillin-
O aminoglycoside combinations on S.
{73 2- \ >, faecium obtained from the patient's
blood cultures immediately prior to
mitral valve excision. Note the lack of
4u, synergy between penicillin and tobra-
25kg/rm Streporrrychn t mycin against this organism when
/0units/mI Penicillin _ compared to synergistic combinations
0 4 8 12 6 20 24 ofpenicillin-gentamicin and penicillin-
HOURS streptomycin.
after initial oral erythromycin therapy, and prior to therapy for endocarditis, are
shown in Table 1. Following combined therapy with ampicillin and tobramycin and
relapse of endocarditis, three morphological variants were isolated from blood
cultures and also evaluated.
Twenty-four hour time-kill curves for penicillin in combination with various
aminoglycosides were performed by Dr. Robert Moellering on the S. faecium iso-
lated from the patient's blood immediately prior to mitral valve excision and re-
placement (Fig. 1). Synergy was readily demonstrable against this organism by
penicillin-streptomycin and penicillin-gentamicin combinations in vitro, but not by
penicillin-tobramycin.
DISCUSSION
Among streptococci, the enterococci are unusual in their relative resistance to a
broad spectrum of antimicrobial agents, and single-agent therapy is rarely
bactericidal against them [2]. Since Hunter's original observations in 1947, it has
become increasingly clear that effective synergistic combinations of antibiotics are
necessary to successfully treat enterococcal endocarditis [1].
Although S. faecalis represents the majority of clinical enterococcal isolates, S.
faecium nonetheless comprises 5-10 percent of these isolates in some series [3,4].
Moreover, major differences exist in antimicrobial susceptibility and resistance to
penicillin-aminoglycoside synergism between these two enterococcal species. The
MIC of penicillin against S. faecium is higher and this organism is more resistant to
a number of different combinations of penicillin and various aminoglycosides than
is S. faecalis [6].
The mechanisms of resistance exhibited by enterococci to penicillin-aminogly-
coside synergy have been investigated. Clinically achievable levels of amino-
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glycosides are generally ineffective against enterococci. This intrinsic low-level
resistance (MIC c 250 isg/ml) is thought to be the result of poor antibiotic pene-
tration of the bacterial cell wall. However, in the presence of antibiotics that in-
terfere with cell wall synthesis, there is enhanced aminoglycoside uptake [7]. In con-
cert, these events are the basis for penicillin-aminoglycoside synergism. Ribosomal
resistance of the 30S subunit to streptomycin and defective uptake ofgentamicin in
the presence of penicillin have been reported mechanisms of resistance among
enterococcal isolates [8,9]. However, in the majority ofinstances, failure of synergy
involves plasmid-mediated production of aminoglycoside-modifying enzymes. For
streptomycin and kanamycin, plasmid-mediated enzymatic inactivation confers
high-level resistance (MIC > 2,000 Ag/ml) and correlates with failure of these
aminoglycosides to exert a synergistic effect when combined with penicillin [10,11].
Plasmid-mediated modifying enzymes have been found in both S. faecalis and S.
faecium' [12]. Currently, approximately one-half of clinical enterococcal isolates
demonstrate high-level resistance to streptomycin and kanamycin [13].
Combinations of penicillin with kanamycin, tobramycin, sisomicin, and
netilmicin have consistently failed to demonstrate synergistic killing of S.faecium in
vitro [6]. This failure of synergy occurs even when high-level resistance to these
aminoglycosides is not present. The mechanism ofresistance appears to be related to
the production of an inactivating enzyme that acetylates the aminoglycoside
substrate at the 6' position1 [14]. The genetic basis for production ofthis enzyme has
not been well-defined and plasmid transfer experiments have thus far been un-
sucessful in demonstrating the encodement of this enzyme by extrachromosomal
DNA [14].
Moellering et al. demonstrated in vivo, utilizing the rabbit model ofendocarditis,
that penicillin and netilmicin were not efficacious in the treatment of endocarditis
caused by a low-level aminoglycoside-resistant strain of S. faecium [6]. Although
combinations of penicillin with tobramycin, kanamycin, or sisomicin were not
evaluated, the authors postulated that the same ineffectual result would have oc-
curred. In the present case, the recurrence of S.faecium endocarditis after six weeks
of therapy with ampicillin and tobramycin confirms the therapeutic and clinical
significance of their data, and emphasizes that tobramycin is not an aminoglycoside
to be used for treatment of serious S. faecium infections.
Bacterial tolerance has been suggested as a possible basis for therapeutic failures,
particularly in the treatment of infections caused by Staphylococcus aureus with
defects in the production ofautolysins. MBCs are generally several-fold higher than
MICs and this phenomenon appears to be associated with the autolysin defect [5].
Lorian has also described the formation of numerous aberrant cross-walls by S.
faecalis grown in the presence of subinhibitory concentrations of penicillin [15].
MBCs were only slightly higher than MICs for the three S. faecium variants ob-
tained from our patient, and they did not appear to be tolerant strains ofS.faecium.
There was no evidence that any of the morphological variants isolated were un-
usually resistant to antibiotics. Therefore, subsequent failure of therapy could not
be explained on the basis of antibiotic resistance patterns. The initial failure of am-
picillin and tobramycin therapy may have allowed the infecting organism to become
better established and more difficult to eradicate from the valve. Alternatively, a
'Wennersten C, Moellering RC Jr: Mechanism of resistance to penicillin-aminoglycoside synergism in
Streptococcusfaecium. Proceedings of the 1th International Congress of Chemotherapy and 19th In-
terscience Conference on Antimicrobial Agents and Chemotherapy 1:710-711, 1979
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persistent focus ofinfection causing the LAD lesion seen by arteriography may have
slowly resolved and accounted for the apparent failure to respond to synergistic
combinations of antibiotics.
In summary, our patient was treated for Streptococcusfaecium endocarditis with
both ampicillin and the aminoglycoside antibiotic, tobramycin. Relapse ofendocar-
ditis might have been anticipated on the basis ofprevious experimental data showing
lack of synergy when tobramycin is used against this organism. This case graphically
illustrates the relevance of synergy studies to therapeutic considerations in the treat-
ment of endocarditis. However, subsequent therapy with synergistic combinations
of antibiotics did not result in cure. The data do not implicate tolerant organisms as
a cause for relapses. Failure oftherapy may have been related to the presence ofpro-
tected organisms in vegetations which were seen on echocardiograms, and also sug-
gested by the presence of a possible coronary artery embolus seen on coronary
arteriograms.
In conclusion, speciation of isolates suspected of causing endocarditis and ade-
quate synergy studies of antibiotic combinations are indicated before a long and ex-
pensive course of therapy with antimicrobial agents is undertaken for this disease.
However, as this case also illustrates, demonstration of synergism in vitro does not
assure clinical cure.
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